Sign in
WithdrawnEarly phase 1

Glucagon-like Peptide-1 in Type 1 Diabetes

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Early phase 1
Started
24 Jun 2020
Ended
24 Sept 2025
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Glucagon-like peptide-1
  • Placebos
Record updated
10 November 2025
Why it stopped
We were unable to obtain GLP-1

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • 40 (20 males, 20 females) individuals with type 1 diabetes aged 18-50 yr
  • HbA1c < 11.0%
  • Body mass index < 40kg • m-2
  • No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)

Who cannot take part

  • Subjects taking any of the following medications will be excluded: non-selective beta blockers,
  • sedative-hypnotics, anticonvulsants, antiparkinsonian drugs, antipsychotics, antidepressants,
  • Subjects on anticoagulant drugs, anemic or with known bleeding diatheses
  • Subjects with a history of severe uncontrolled hypertension (i.e., blood pressure greater than 160/100), heart disease, cerebrovascular incidents
  • Hepatic failure /jaundice
  • Screening Laboratory Tests Exclusion Criteria
  • WBC lower than 3 thou/ul or greater than 14 thou/ul
  • Liver function tests: SGOT and SGPT greater than twice upper limit of normal range (i.e. > 80 U/L)
  • TBil > 2 mg/dl
  • Creatinine > 1.6 mg/dl
  • Alkaline phosphatase > 150U/L
  • Hepatic transaminase > 2x normal
  • Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmias, ischemic tachycardia, S-T segment deviations, etc.) from history or from cardiac stress testing in subjects ≥ 40 years old
  • Subjects unable to give voluntary informed consent
  • Pregnancy
  • mood stabilizers, CNS stimulants, opioids, hallucinogens
  • Subjects unwillingness or inability to comply with approved contraception measures
  • Pneumonia
  • Abnormal results following screening tests and physical examination that are clinically significant
  • Acute cerebrovascular/ neurological deficit
  • Fever greater than 38.0 C
  • Hematocrit lower than 32

Where in United States

  • University of MarylandBaltimore, United States

About the trial

What the trial wants to find out

The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.

The 3 groups in the trial

  • Placebo 1Placebo, for comparison

    The participants will be randomized to placebo infusion.

    Treatment: Placebos

  • Placebo 2Placebo, for comparison

    The participants will be randomized to placebo infusion.

    Treatment: Placebos

  • GLP-1Treatment being tested

    The participants will be randomized to Glucagon-like peptide-1 infusion.

    Treatment: Glucagon-like peptide-1

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Reducing Hypoglycemic, Pro-coagulant and Pro-atherothrombotic Responses and Preventing Hypoglycemia Associated Autonomic Failure in Type 1 DM. The Effects of Glucagon-like Peptide-1
Record updated
10 November 2025